Cargando…
Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170280/ https://www.ncbi.nlm.nih.gov/pubmed/37181342 http://dx.doi.org/10.21037/atm-23-341 |
| _version_ | 1785039195635449856 |
|---|---|
| author | Ferrucci, Pier Francesco |
| author_facet | Ferrucci, Pier Francesco |
| author_sort | Ferrucci, Pier Francesco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10170280 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101702802023-05-11 Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors Ferrucci, Pier Francesco Ann Transl Med Editorial Commentary AME Publishing Company 2023-02-20 2023-04-28 /pmc/articles/PMC10170280/ /pubmed/37181342 http://dx.doi.org/10.21037/atm-23-341 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Ferrucci, Pier Francesco Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title | Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title_full | Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title_fullStr | Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title_full_unstemmed | Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title_short | Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors |
| title_sort | lenvatinib/pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (pd-1)/programmed death ligand-1 (pd-l1) inhibitors |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170280/ https://www.ncbi.nlm.nih.gov/pubmed/37181342 http://dx.doi.org/10.21037/atm-23-341 |
| work_keys_str_mv | AT ferruccipierfrancesco lenvatinibpembrolizumabassecondlinetreatmentforadvancedmelanomapatientsrefractorytoprogrammeddeath1pd1programmeddeathligand1pdl1inhibitors |